CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Callisto Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Callisto Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 1609
Phone: (212) 297-0010p:212 297-0010 New York, NY  10170  United States Fax: (212) 297-0020f:212 297-0020

This company was Merged or Acquired on 1/17/2013.
This company ceased filing statements with the SEC on 1/22/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Callisto Pharmaceuticals, Inc. (Callisto) is a development-stage biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates as a holding company through two controlled subsidiaries: Synergy Pharmaceuticals, Inc. (Synergy) (41% owned) and Callisto Research Labs, LLC (100% owned). Synergy owns one inactive subsidiary, IgX, Ltd (Ireland). All of its drug candidates, plecanatide and SP-333 to treat GI disorders and diseases, are being developed by Synergy. Synergy’s drug candidates include Plecanatide, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C), and SP-333, which is a second generation GC-C receptor agonist, SP-333, which is in pre-clinical development to treat gastrointestinal inflammatory diseases.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Gabriele M.Cerrone 40 5/1/2003 5/1/2003
Chief Executive Officer, Chief Scientific Officer, Director Gary S.Jacob 65 10/1/2004 5/1/2003
Senior Vice President - Finance, Secretary Bernard F.Denoyer 64 12/1/2007 1/15/2004
Independent Director John P.Brancaccio 64 4/1/2004 4/1/2004
Independent Director Randall K.Johnson 65 2/14/2005 2/14/2005

Business Names
Business Name
Callisto Research Labs, LLC
CLSP
IgX, Ltd.
Synergy Pharmaceuticals, Inc.
WBTN

General Information
Outstanding Shares: 158,965,565 (As of 11/19/2012)
Shareholders: 125
Stock Exchange: OTC
Federal Tax Id: 133894575
Fax Number: (212) 297-0020


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023